Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics
Y Duan, K Gong, S Xu, F Zhang, X Meng… - Signal Transduction and …, 2022 - nature.com
Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …
NAFLD and cardiovascular diseases: a clinical review
P Kasper, A Martin, S Lang, F Kuetting… - Clinical research in …, 2021 - Springer
Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …
Western countries and affects approximately 25% of the adult population. Since NAFLD is …
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
J Aron-Wisnewsky, C Vigliotti, J Witjes, P Le… - Nature Reviews …, 2020 - nature.com
Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes
mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease …
mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease …
Nonalcoholic steatohepatitis: a review
Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic
fatty liver disease (NAFLD) and is associated with disease progression, development of …
fatty liver disease (NAFLD) and is associated with disease progression, development of …
Adverse effects of statin therapy: perception vs. the evidence–focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
F Mach, KK Ray, O Wiklund, A Corsini… - European heart …, 2018 - academic.oup.com
Aims To objectively appraise evidence for possible adverse effects of long-term statin
therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for …
therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for …
Non-alcoholic fatty liver disease and dyslipidemia: an update
N Katsiki, DP Mikhailidis, CS Mantzoros - Metabolism, 2016 - Elsevier
Non-alcoholic fatty liver (NAFLD) is the most common liver disease worldwide, progressing
from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic …
from simple steatosis to necroinflammation and fibrosis (leading to non-alcoholic …
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Given the high prevalence and rising incidence of non-alcoholic fatty liver disease (NAFLD),
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …
the absence of approved therapies is striking. Although the mainstay of treatment of NAFLD …
[HTML][HTML] KASL clinical practice guidelines: management of nonalcoholic fatty liver disease
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …
Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study
Background & Aims Patients with non-alcoholic fatty liver disease (NAFLD) are at increased
chance for cardiovascular events (CVEs). Severity of liver fibrosis is used to determine …
chance for cardiovascular events (CVEs). Severity of liver fibrosis is used to determine …
Therapies in non‐alcoholic steatohepatitis (NASH)
AM Oseini, AJ Sanyal - Liver International, 2017 - Wiley Online Library
The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in
the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or …
the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or …